Quarterly ResultAug 6, 2026, 04:13 PM
IN8bio Q2 Net Loss $4.8M; Cash $18.0M; Advances γδ T Cell Programs
AI Summary
IN8bio reported its second-quarter 2026 financial results, with a net loss of $4.8 million, or $0.25 per share, and a cash position of $18.0 million as of June 30, 2026. The company highlighted significant clinical and scientific advancements, including updated data for its DeltEx™ Drug Resistant Immunotherapy (DRI) in glioblastoma (GBM) showing improved median overall survival and progression-free survival. Additionally, IN8bio is progressing its next-generation gamma delta (γδ) T cell engager platform (INB-619), with initial in vivo data anticipated in the second half of 2026.
Key Highlights
- Net loss for Q2 2026 was $4.8 million, or $0.25 per basic and diluted common share.
- Cash position as of June 30, 2026, was $18.0 million.
- Research and Development (R&D) expenses were $2.5 million for Q2 2026, consistent year-over-year.
- General and administrative (G&A) expenses decreased to $2.4 million for Q2 2026 from $2.7 million in Q2 2025.
- DeltEx™ DRI in glioblastoma (GBM) showed median overall survival exceeding 19.5 months.
- DeltEx™ DRI demonstrated median progression-free survival of 13.0 months versus 6.6 months for standard-of-care.
- Initial in vivo preclinical data for INB-619, a γδ T cell engager, is expected in the second half of 2026.
Price Impact
More from INAB